EUVIMEDEUVIMED entdecken
Crossref

The Efficacy and Safety of Denosumab for Treating Hypercalcemia in Primary Hyperparathyroidism: A Retrospective Study

An Song iD, Yingyu Chen iD, Rong Chen iD, Shuzhong Liu, Liyuan Kou, Jiajia Wang iD, Min Nie, Yan Jiang iD, Mei Li iD, Weibo Xia iD, Xiaoping Xing iD, Ou Wang iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von An Song und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of…. Hauptthemen laut MEDLINE: Hypercalcemia, Denosumab, Hyperparathyroidism, Primary, Bone Density Conservation Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Peking Union Medical College Hospital Young Reserve Talent Development Program, CMA Young and Middle-aged Doctors Outstanding Development Program-Osteoporosis Specialized Scientific Research Fund Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Denosumab is approved for treating hypercalcemia of malignancy, but data on its efficacy for hypercalcemia related to primary hyperparathyroidism (PHPT) are limited.

Objective

To compare the efficacy and safety of denosumab with zoledronic acid in PHPT-related hypercalcemia.

Methods

We retrospectively collected data from 29 PHPT patients with moderate/severe hypercalcemia (corrected serum calcium [CSC] ≥ 3.0 mmol/L) treated with denosumab (60 or 120 mg; Dmab group) and CSC-matched 29 PHPT patients treated with zoledronic acid (4 mg; ZA group). The primary efficacy outcome was the change of CSC (ΔCa), while secondary outcomes included the response proportion, time to response, and duration of response. Safety data were also collected.

Results

Both groups showed significant reductions in CSC levels (Dmab: 3.37 ± 0.37 mmol/L to 2.64 ± 0.33 mmol/L, P < .01; ZA: 3.41 ± 0.32 mmol/L to 2.57 ± 0.23 mmol/L, P < .01), with similar ΔCa. In the Dmab group, 82.8% (24/29) responded with CSC levels below 3.0 mmol/L, and 72.4% (21/29) achieved complete response (CR, serum CSC less than 2.7 mmol/L), comparable to the ZA group. The time to CR was shorter for ZA (3.0 vs 7.0 days, P < .01), while Dmab had a longer duration of response (19.0 vs 13.0 days, P = .02). Hypocalcemia occurred in 6.9% (2/29, both with chronic kidney disease stage 3b) of Dmab patients, while none in the ZA group.

Conclusion

A single 60-mg dose of denosumab effectively reduces serum calcium levels in PHPT patients with moderate/severe hypercalcemia, at least maintaining efficacy for a median of nearly 3 weeks without serious adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypercalcemiaDenosumabHyperparathyroidism, PrimaryBone Density Conservation AgentsHumansRetrospective StudiesMaleFemaleMiddle AgedAgedTreatment OutcomeCalciumZoledronic AcidAdultAged, 80 and over

Stichwörter der Autor:innen

denosumabefficacyhypercalcemiaprimary hyperparathyroidismsafety

Substanzen

DenosumabBone Density Conservation AgentsCalciumZoledronic Acid

Autor:innen und Institutionen

  • Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
  • Department of Orthopaedic Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.

ORCID-Profile: An Song, Yingyu Chen, Rong Chen, Jiajia Wang, Yan Jiang, Mei Li, Weibo Xia, Xiaoping Xing, Ou Wang

Förderung

  • National Natural Science Foundation of China
  • Peking Union Medical College Hospital Young Reserve Talent Development Program
  • CMA Young and Middle-aged Doctors Outstanding Development Program-Osteoporosis Specialized Scientific Research Fund Project
  • Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
  • National High Level Hospital Clinical Research Funding

Zitieren

APA

Song, A., Chen, Y., Chen, R., Liu, S., Kou, L., Wang, J., Nie, M., Jiang, Y., Li, M., Xia, W., Xing, X., & Wang, O. (2025). The Efficacy and Safety of Denosumab for Treating Hypercalcemia in Primary Hyperparathyroidism: A Retrospective Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf107

Vancouver

Song A, Chen Y, Chen R, Liu S, Kou L, Wang J, et al. The Efficacy and Safety of Denosumab for Treating Hypercalcemia in Primary Hyperparathyroidism: A Retrospective Study. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf107

BibTeX
@article{Song2025,
  author = {Song, An and Chen, Yingyu and Chen, Rong and Liu, Shuzhong and Kou, Liyuan and Wang, Jiajia and Nie, Min and Jiang, Yan and Li, Mei and Xia, Weibo and Xing, Xiaoping and Wang, Ou},
  title = {The Efficacy and Safety of Denosumab for Treating Hypercalcemia in Primary Hyperparathyroidism: A Retrospective Study},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf107}
}
Kostenlos starten →